Eupraxia Pharmaceuticals (EPRX) Capital Expenditures (2023 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Capital Expenditures came in at -$326953.0 in Q1 2026, down 93.41% year-on-year from -$5.0 million in Q1 2025, and down 133.21% on a QoQ basis from $984593.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Capital Expenditures (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 4 years of Capital Expenditures data on file, last reported at -$326953.0 in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 93.41% year-over-year to -$326953.0 in Q1 2026; TTM through Mar 2026 was $431038.0, a 842.81% increase from a year earlier, with the FY2025 full-year figure at $588947.0, up 465.06% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$326953.0, down from $984593.0 in the prior quarter.
- Over the last five years, Capital Expenditures for EPRX reached as high as $984593.0 in Q4 2025 and fell as low as -$326953.0 in Q1 2026.
- Historically, Capital Expenditures has averaged $33815.2 across 4 years, with a median of -$9602.0 in 2023.
- On a YoY basis, Capital Expenditures climbed as much as 499.85% in 2025 and fell as far as 2389.97% in 2025.
- Year by year, Capital Expenditures stood at $97369.0 in 2023, then soared by 68.57% to $164139.0 in 2024, then surged by 499.85% to $984593.0 in 2025, then plunged by 133.21% to -$326953.0 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were -$326953.0 in Q1 2026, $984593.0 in Q4 2025, and -$60377.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | -326,953.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -326,953.00 |
| Mar 31, 2026 | -326,953.00 |
| Dec 31, 2025 | 984,593.00 |
| Dec 31, 2025 | 984,593.00 |
| Sep 30, 2025 | -60,377.00 |
| Sep 30, 2025 | -60,377.00 |
| Jun 30, 2025 | -166,225.00 |
| Jun 30, 2025 | -166,225.00 |
| Mar 31, 2025 | -169,044.00 |
| Mar 31, 2025 | -169,044.00 |
| Dec 31, 2024 | 164,139.00 |
| Dec 31, 2024 | 164,139.00 |
| Sep 30, 2024 | -42,275.00 |
| Sep 30, 2024 | -42,275.00 |
| Jun 30, 2024 | -10,848.00 |
| Jun 30, 2024 | -10,848.00 |
| Mar 31, 2024 | -6,789.00 |
| Mar 31, 2024 | -6,789.00 |
| Dec 31, 2023 | 97,369.00 |
| Dec 31, 2023 | 97,369.00 |